Vaxart (VXRT) reported a Q1 net loss late Tuesday of $0.07 per diluted share, narrowing from the loss of $0.14 a year earlier.
Two analysts polled by FactSet expected a loss of $0.07.
Revenue in the three months ended March 31 rose to $20.9 million from $2.18 million a year earlier.
The company had cash, cash equivalents and investments of $41.9 million as of March 31 with a cash runway expected into Q1 2026.
Vaxart appointed Jeroen Grasman as chief financial officer, effective May 19. He succeeds Phillip Lee, who resigned for personal reasons, the company said.
Grasman most recently was CFO at AltruBio.
Vaxart shares rose 5.9% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。